Clinical Trial Update: A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) [Phase 3]

View source ↗

Summary

Phase 3 study measuring upadacitinib in adolescents and adults with moderate to severe atopic dermatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2022-03-28